Here we go again: COVID-19 hospital admissions have inched upward in the United States since early July in a small-scale echo of the three previous summers.
With an updated vaccine still months away, this summer bump in new hospitalizations might be concerning, but the number of patients is far lower than before. A look at what we know:
HOW BAD IS THE SPIKE?
For the week ending July 29, COVID-19 hospital admissions were at 9,056. That's an increase of about 12% from the previous week.
But it's a far cry from past peaks, like the 44,000 weekly hospital admissions in early January, the nearly 45,000 in late July 2022, or the 150,000 admissions during the omicron surge of January 2022.
“It is ticking up a little bit, but it’s not something that we need to raise any alarm bells over,” said Dr. David Dowdy, an infectious disease epidemiologist at Johns Hopkins Bloomberg School of Public Health.
It’s likely that infections are rising too, but the data is scant. Federal authorities ended the public health emergency in May, so the Centers for Disease Control and Prevention and many states no longer track the number of positive test results.
WHAT ABOUT DEATHS?
Since early June, about 500 to 600 people have died each week. The number of deaths appears to be stable this summer, although past increases in deaths have lagged behind hospitalizations.
HOW ARE WE TRACKING THE VIRUS?
The amount of the COVID-19 virus in sewage water has been rising since late June across the nation. In the coming weeks, health officials say they'll keep a close eye on wastewater levels as people return from summer travel and students go back to school.
Higher levels of COVID-19 in wastewater concentrations are being found in the Northeast and South, said Cristin Young, an epidemiologist at Biobot Analytics, the CDC's wastewater surveillance contractor.
“It’s important to remember right now the concentrations are still fairly low,” Young said, adding it's about 2.5 times lower than last summer.
“There are a couple that we’re watching, but we’re not seeing anything like delta or omicron,” Young said, referencing variants that fueled previous surges.
And mutations in the virus don't necessarily make it more dangerous.
“Just because we have a new subvariant doesn’t mean that we are destined to have an increase in bad outcomes," Dowdy said.
WHEN IS THE NEW VACCINE COMING?
This fall, officials expect to see updated COVID-19 vaccines that contain one version of the omicron strain, called XBB.1.5. It’s an important change from today’s combination shots, which mix the original coronavirus strain with last year’s most common omicron variants.
It's not clear exactly when people can start rolling up their sleeves for what officials hope is an annual fall COVID-19 shot. Pfizer, Moderna and smaller manufacturer Novavax all are brewing doses of the XBB update but the Food and Drug Administration will have to sign off on each, and the CDC must then issue recommendations for their use.
Dr. Mandy Cohen, the new CDC director, said she expects people will get their COVID-19 shots where they get their flu shots — at pharmacies and at work — rather than at dedicated locations that were set up early in the pandemic as part of the emergency response.
“This is going to be our first fall and winter season coming out of the public health emergency, and I think we are all recognizing that we are living with COVID, flu, and RSV," Cohen told The Associated Press last week. “But the good news is we have more tools than ever before.”
AP Medical Writers Lauran Neergaard and Mike Stobbe contributed to this report.
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group. The AP is solely responsible for all content.
After two decades of engineering, over $10 billion, and a series of delays, the most powerful telescope built by NASA is finally scheduled to launch on Saturday. The James Webb Space Telescope was built to provide a fresh look at the universe by detecting light that is invisible to the human eye and to reveal new information about the universe's oldest stars and galaxies. Lou Strolger, observatory scientist and deputy head of instruments division, space telescope, joins Cheddar News.
Carlo and Baker kick off the weirdest week of the year with all the news you missed over the holiday weekend, including calls for the CDC to shorten its isolation window as Omicron sweeps through the country.
The 2022 Winter Olympics will be without some of hockey's biggest players. The NHL and the NHL Player's Association have agreed to not participate in the men's hockey tournament at the Games in Beijing next year. The league has been forced to postpone some games because of a rise in COVID-19 cases among players. Washington Post sports reporter Samantha Pell joins Cheddar News' Closing Bell to discuss what this could mean for the Winter Olympics and the sport of hockey.
The National Highway Traffic Safety Administration has opened a formal investigation into Tesla. The agency is looking into about 580,000 Tesla vehicles, and a feature called 'Passenger Play' which allows drivers to play video games on the center touch screen. The feature previously only worked when a vehicle was in park; but, the NHTSA says it has confirmed that the feature has been available while vehicles are in motion since December of 2020. iSeeCars.com executive analyst Karl Brauer joins Cheddar News' Closing Bell to discuss.
Baron Davis and Kate Hudson want you to bring cannabis home for the holidays. The cannabis-infused seltzer brand Cann released a new spot featuring the actress and former NBA player. The campaign comes hand in hand with Cann's launch of a new holiday bundle, which includes its product with Hudson's King Street Vodka. Davis and Hudson are also Cann investors. Cheddar cannabis reporter Chloe Aiello spoke to Davis about his involvement with the company and its new campaign.
Healthcare workforce management platform ShiftMed
recently announced a $45 million funding round.
The company's platform connects nurses and healthcare professionals to hospitals and other healthcare providers.
ShiftMed's new funding comes amid widespread labor shortages in the healthcare sector. The company's CEO Todd Walrath joins Cheddar News' Closing Bell to discuss.
Universities like UCLA, Yale, and Duke have announced they're implementing remote learning amid the COVID omicron variant surge, despite President Biden recommending that K-12 schools should continue in-person education. Jared C. Bass, senior director for Higher Education at American Progress, joined Cheddar to break down what institutions of higher education might be considering differently. "I think some universities are allowing periods of a bit of a respite to allow students to get testing and make sure when they do return back to campus that they're healthy," he noted.
Supply chain issues have become one of the biggest roadblocks for the U.S. EV market, with production woes likely to stunt the industry's growth in 2022. Rich Steinberg, electric vehicle expert and industry advisor, told Cheddar that the Biden administration investing in domestic mining for essential minerals used in battery manufacturing — such as lithium — could help alleviate the bottlenecks. "Some of those same materials are available domestically, they just haven't been prioritized," he said, noting the paradox between green tech and "dirty" mining. "The good news is that there are ways to extract those materials cleanly."
Hyperfine, the pioneer of the very first FDA-approved portable MRI device, made its public debut on the Nasdaq via a SPAC merger. CEO Dave Scott joined Cheddar's "Opening Bell" to discuss the IPO launch, the company's valuation at $580 million, and the impact of its machine called Swoop. "We can roll an MRI system, our MRI Swoop system, right into the room where you are, right up to your patient bedside, and scan you right there and get an image in less than an hour," he explained.
Dr. Rob Davidson, Executive Director of the Committee to Protect Health Care and an ER Physician in West Michigan, joins Cheddar News to break down the expectations of Pfizer's new COVID-19 treatment pill.
